Scales as outcome measures for Alzheimer's disease

[1]  J. Morris,et al.  Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .

[2]  Takeshi Iwatsubo.  [Alzheimer's disease Neuroimaging Initiative (ADNI)]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[3]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[4]  C. Jack,et al.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.

[5]  Maria C. Carrillo,et al.  Maximizing the Alzheimer's Disease Neuroimaging Initiative II , 2009, Alzheimer's & Dementia.

[6]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[7]  D. Harvey,et al.  Longitudinal Changes in Memory and Executive Functioning are Associated with longitudinal change in instrumental activities of daily living in older Adults , 2009, The Clinical neuropsychologist.

[8]  P. Snyder,et al.  Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. , 2009, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[9]  Adriana M. Seelye,et al.  Status of computerized cognitive testing in aging: A systematic review , 2008, Alzheimer's & Dementia.

[10]  Ramon Diaz-Arrastia,et al.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. , 2008, JAMA.

[11]  V. Pankratz,et al.  Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. , 2008, Archives of general psychiatry.

[12]  Kathleen Baynes,et al.  The measurement of everyday cognition (ECog): scale development and psychometric properties. , 2008, Neuropsychology.

[13]  A. Mitnitski,et al.  O3-07-03: Patient-care partner goals of dementia treatment Comparing clinical trial and web-based accounts , 2008, Alzheimer's & Dementia.

[14]  Y. Graaf,et al.  P1-257: Visual rating of the hippocampus in nondemented elders: Can it differentiate between hippocampal volume and other indices of brain atrophy? , 2008, Alzheimer's & Dementia.

[15]  B. Winblad,et al.  Safety and efficacy of galantamine in subjects with mild cognitive impairment , 2008, Neurology.

[16]  P. Marquis,et al.  PHP82 RECENT TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA , 2008 .

[17]  H. Feldman,et al.  Transition from Cognitively Impaired Not Demented to Alzheimer’s Disease: An Analysis of Changes in Functional Abilities in a Dementia Clinic Cohort , 2008, Dementia and Geriatric Cognitive Disorders.

[18]  D. Paleacu,et al.  Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6‐week, double‐blind, placebo‐controlled study , 2008, International journal of geriatric psychiatry.

[19]  Cherisse McKay,et al.  The Repeatable Battery for The Assessment of Neuropsychological Status (RBANS): Clinical Utility in a Traumatic Brain Injury Sample , 2008, The Clinical neuropsychologist.

[20]  W. Jones,et al.  Automated Neuropsychological Assessment Metrics (Anam) and Woodcock-Johnson III Tests of Cognitive Ability: A Concurrent Validity Study , 2008, The Clinical neuropsychologist.

[21]  L. Schneider.  Prevention therapeutics of dementia , 2008, Alzheimer's & Dementia.

[22]  M. Biondi,et al.  Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. , 2007, Experimental and clinical psychopharmacology.

[23]  Leslie M. Shaw,et al.  PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging Initiative , 2007, Neurosignals.

[24]  Jeremy C Hobart,et al.  Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations , 2007, The Lancet Neurology.

[25]  Karen Marder,et al.  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease , 2007, Current neurology and neuroscience reports.

[26]  Martin Koller,et al.  A neuropsychological test battery for use in Alzheimer disease clinical trials. , 2007, Archives of neurology.

[27]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[28]  Joylee Wu,et al.  The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set , 2007, Alzheimer disease and associated disorders.

[29]  D. Harvey,et al.  Cognitive and neuroimaging predictors of instrumental activities of daily living , 2007, Journal of the International Neuropsychological Society.

[30]  S. Fay,et al.  Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. , 2007, Neurology.

[31]  C. Lyketsos.  Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments , 2007, International Psychogeriatrics.

[32]  J. Morris,et al.  Validity and reliability of the AD8 informant interview in dementia , 2006, Neurology.

[33]  U. S. D. O. H. A. H. S. F. C. Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[34]  L. Schneider,et al.  ADCS Prevention Instrument Project: Overview and Initial Results , 2006, Alzheimer disease and associated disorders.

[35]  L. Thal,et al.  ADCS Prevention Instrument Project: Pharmacoeconomics: Assessing Health-related Resource Use Among Healthy Elderly , 2006, Alzheimer disease and associated disorders.

[36]  D. Harvey,et al.  MCI is Associated With Deficits in Everyday Functioning , 2006, Alzheimer disease and associated disorders.

[37]  C. Gualtieri,et al.  Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. , 2006, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[38]  K. Rockwood.  Capacity, population aging and professionalism , 2006, Canadian Medical Association Journal.

[39]  Robert K. Heaton,et al.  Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. , 2006, The American journal of psychiatry.

[40]  Timo Grimmer,et al.  Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome , 2006, International journal of geriatric psychiatry.

[41]  G. Fillenbaum,et al.  Memory Complaint Is Not Necessary for Diagnosis of Mild Cognitive Impairment and Does Not Predict 10‐Year Trajectories of Functional Disability, Word Recall, or Short Portable Mental Status Questionnaire Limitations , 2006, Journal of the American Geriatrics Society.

[42]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[43]  P. Tariot,et al.  A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Safety and Tolerability of Two Doses of Divalproex Sodium in Outpatients with Probable Alzheimers Disease , 2005 .

[44]  P. Maruff,et al.  Examination of the use of cognitive domains in postoperative cognitive dysfunction after coronary artery bypass graft surgery. , 2005, The Annals of thoracic surgery.

[45]  W. Jagust,et al.  Degree of discrepancy between self and other‐reported everyday functioning by cognitive status: dementia, mild cognitive impairment, and healthy elders , 2005, International journal of geriatric psychiatry.

[46]  O. Gureje,et al.  The Stick Design test: A new measure of visuoconstructional ability , 2005, Journal of the International Neuropsychological Society.

[47]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[48]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[49]  P. Zandi,et al.  A Population Study of Alzheimer’s Disease: Findings From the Cache County Study on Memory, Health, and Aging , 2005, Care Management Journals.

[50]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[51]  W. Jagust,et al.  Everyday functioning in relation to cognitive functioning and neuroimaging in community-dwelling Hispanic and Non-Hispanic older adults , 2004, Journal of the International Neuropsychological Society.

[52]  Ronald A. Cohen,et al.  Executive Impairments Predict Functional Declines in Vascular Dementia , 2004, The Clinical neuropsychologist.

[53]  J. Johnson,et al.  Correlational Analysis of Microcog: Assessment of Cognitive Functioning with the Wechsler Adult Intelligence Scale—III for a Clinical Sample of Veterans , 2003, Psychological reports.

[54]  Avraham Schweiger,et al.  Validity of a novel computerized cognitive battery for mild cognitive impairment , 2003, BMC geriatrics.

[55]  Sarah Tomaszewski Farias,et al.  The relationship between neuropsychological performance and daily functioning in individuals with Alzheimer's disease: ecological validity of neuropsychological tests. , 2003, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[56]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[57]  K. Rockwood,et al.  Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations , 2002, International journal of geriatric psychiatry.

[58]  M. Grossman,et al.  Visual perceptual functions predict instrumental activities of daily living in patients with dementia. , 2002, Neuropsychiatry, neuropsychology, and behavioral neurology.

[59]  M. Matsui,et al.  [The Japanese version of RBANS (Repeatable Battery for the Assessment of Neuropsychological Status)]. , 2002, No to shinkei = Brain and nerve.

[60]  G. Ratcliff,et al.  Sensitivity and Specificity of Cognitive and Functional Screening Instruments for Dementia: The Indo‐U.S. Dementia Epidemiology Study , 2002, Journal of the American Geriatrics Society.

[61]  L. Schneider,et al.  A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[62]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[63]  D. Erlanger,et al.  Development and validation of the cognitive stability index, a Web-based protocol for monitoring change in cognitive function , 2000 .

[64]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[65]  L. Thal,et al.  Analysis of longitudinal data in an Alzheimer's disease clinical trial. , 2000, Statistics in medicine.

[66]  S. Salloway,et al.  Prediction of Functional Status from Neuropsychological Tests in Community-Dwelling Elderly Individuals , 2000, The Clinical neuropsychologist.

[67]  D. Zaitchik,et al.  Predicting conversion to Alzheimer disease using standardized clinical information. , 2000, Archives of neurology.

[68]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[69]  S. Gauthier,et al.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[70]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[71]  C. Randolph,et al.  The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. , 1998, Journal of clinical and experimental neuropsychology.

[72]  R. Hamman,et al.  Executive Cognitive Abilities and Functional Status Among Community‐Dwelling Older Persons in the San Luis Valley Health and Aging Study , 1998, Journal of the American Geriatrics Society.

[73]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[74]  R. Mohs,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). , 1995, Neurology.

[75]  B. Reisberg,et al.  The Neglected Half of Alzheimer Disease: Cognitive and Functional Concomitants of Severe Dementia , 1994, Journal of the American Geriatrics Society.

[76]  D. Knopman,et al.  The Clinician Interview‐ Based Impression (CIBI) , 1994, Neurology.

[77]  P. Rabbitt,et al.  Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. , 1994, Dementia.

[78]  S W Lagakos,et al.  Size and power of two-sample tests of repeated measures data. , 1993, Biometrics.

[79]  P. Truax,et al.  Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist. , 1992, Psychology and aging.

[80]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[81]  J. Baty,et al.  Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention , 1992, Annals of neurology.

[82]  N. Cutler,et al.  A New Assessment Tool for Neuropsychopharmacologic Research: The Computerized Neuropsychological Test Battery , 1991, Journal of geriatric psychiatry and neurology.

[83]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[84]  Keith Wesnes,et al.  The cognitive drug research computerized assessment system for demented patients: A validation study , 1991 .

[85]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[86]  J. Morris,et al.  Validation of clinical diagnostic criteria for Alzheimer's disease , 1988, Annals of neurology.

[87]  A. Korten,et al.  Assessment of Cognitive Decline in the Elderly by Informant Interview , 1988, British Journal of Psychiatry.

[88]  E. Helmes,et al.  Standardization and validation of the Multidimensional Observation Scale for Elderly Subjects (MOSES). , 1987, Journal of gerontology.

[89]  R. Terry,et al.  Senile dementia of the Alzheimer type , 1983, Annals of neurology.

[90]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[91]  T. Kurosaki,et al.  Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.

[92]  I M Wilkinson,et al.  Psychogeriatric Dependency Rating Scales (PGDRS) A Method of Assessment for Use by Nurses , 1980, British Journal of Psychiatry.

[93]  D. Andrich.  A rating formulation for ordered response categories , 1978 .

[94]  Benjamin D. Wright,et al.  Solving measurement problems with the Rasch model. , 1977 .

[95]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[96]  M. R. Novick,et al.  Statistical Theories of Mental Test Scores. , 1971 .

[97]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[98]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[99]  Graeme Hutcheson,et al.  Rasch Models for Measurement , 2011 .

[100]  D. Hosford,et al.  Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[101]  S. Azen,et al.  Detecting cognitive impairment in primary care: performance assessment of three screening instruments. , 2007, Journal of Alzheimer's disease : JAD.

[102]  H. Hussain.  Restriction in complex activities of daily living in MCI: impact on outcome. , 2007, Neurology.

[103]  Alija Kulenović,et al.  Standards for Educational and Psychological Testing , 1999 .

[104]  K. Dagerman,et al.  The n e w e n g l a n d j o u r n a l of m e d i c i n e Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer’s Disease , 2006 .

[105]  J. Tornatore,et al.  Self-administered screening for mild cognitive impairment: initial validation of a computerized test battery. , 2005, The Journal of neuropsychiatry and clinical neurosciences.

[106]  P. Tariot,et al.  A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. , 2005, Current Alzheimer research.

[107]  C. Jack,et al.  Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. , 2004, Archives of neurology.

[108]  T. Patterson,et al.  UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. , 2001, Schizophrenia bulletin.

[109]  C. Cotman,et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.

[110]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[111]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[112]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[113]  J. Morris,et al.  Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .

[114]  S. Salloway,et al.  Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. , 1996, The Journal of neuropsychiatry and clinical neurosciences.

[115]  S. McElroy,et al.  Valproate in the treatment of behavioral agitation in elderly patients with dementia. , 1995, The Journal of neuropsychiatry and clinical neurosciences.

[116]  R. Mohs,et al.  Alzheimer's Disease Assessment Scale (ADAS). , 1988, Psychopharmacology bulletin.

[117]  K. Davis,et al.  Oral physostigmine in Alzheimer's disease. , 1983, Psychopharmacology bulletin.

[118]  B. Wright,et al.  Best Test Design. Rasch Measurement. , 1979 .

[119]  S. Katz.  Studies of illness in the aged , 1963 .